Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Selects Bluebee as Data Processing Partner for MammaPrint, BluePrint IVD Kit

NEW YORK (GenomeWeb) – Agendia announced today that it has signed an agreement to have Dutch genomic data analysis firm Bluebee provide data processing services for a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The kit allows Agendia's MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay to be performed by labs using existing NGS instruments, rather than sending them to the company for centralized processing. It is currently being validated with collaborators in anticipation of a European launch in early 2018.

According to Agendia, Bluebee will help provide secure global access to test kit results, while ensuring that all data complies with local data privacy and residency regulations. Additional terms of the deal were not disclosed.

"When choosing a data processing partner, it was important for us to work with a team that could deliver these results in a highly secure form," Marjolaine Baldo, Agendia's commercial vice president for Europe, the Middle East, and Africa, said in a statement. "We are very pleased to partner with Bluebee as we finalize the development of the MammaPrint BluePrint Kit ahead of European launch."

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.